Q2 2025 Aytu Biopharma Inc Earnings Call Transcript

Feb 12, 2025 / 09:30 PM GMT

Release Date Price: $1.39 (-2.11%)

Transcript 10-Q8-K

Key Points

Positve

Aytu BioPharma Inc (AYTU) reported its seventh consecutive quarter of positive adjusted EBITDA and second consecutive quarter of net income.
The company successfully returned both its ADHD and pediatric portfolios to positive sequential prescription growth.
Aytu BioPharma Inc (AYTU) achieved $2 million in future annual cost savings through corporate optimization initiatives.
The company has a strong cash position with a balance of $20.4 million at the end of December 2024.
Aytu BioPharma Inc (AYTU) is leveraging its A2RX Connect platform to improve patient access and differentiate its products in the market.

Negative

ADHD net revenue decreased 17% year-over-year due to normalization of the ADHD stimulant supply chain.
Gross margin for the second quarter was 66%, down from 78% in the same quarter last year, due to higher costs from transitioning manufacturing.
The company is still working through higher-cost ADHD inventory, which is impacting gross margins.
Operating expenses remain a concern, although there have been reductions, further optimization is needed.
The company faces challenges in returning ADHD franchise revenue to previous levels of $16-17 million per quarter.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AYTU.OQ - Aytu Biopharma Inc
Q2 2025 Aytu Biopharma Inc Earnings Call
Feb 12, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day everyone, and welcome to the A2 BioPharma fiscal 2025 Q2 earnings call.

At this time, all participants have been placed on a listen-only mode. If you have any questions or comments during the presentation, you may press one on your phone to enter the question queue at any time, and we will open the floor for your questions and comments after the presentation.

It is not my pleasure to turn the floor over to your host Robert Bloom. Sir, the floor is yours.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
All right, thank you very much and good afternoon,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.